The forgotten endpoint problem isn't a sophisticated supply chain attack or a novel vulnerability. It's basic blocking and ...
The FDA proposes MRD negativity as an accelerated approval end point to speed access to novel myeloma therapies.
Fortinet has confirmed that attackers are already exploiting a 9.1-rated zero-day vulnerability. Emergency security update ...
Bitdefender announced Attack Surface Assessment, a complimentary evaluation that helps organizations identify and reduce hidden internal cyber risk.
Tralokinumab is effective and safe for the treatment of patients with moderate to severe AD through 6 total years of treatment.
(Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, ...
Several patient and disease advocacy organizations have responded to the Center for Drug Evaluation and Research's (CDER) ...
In a small phase II study of patients with KRAS G12C-mutated NSCLC, poor performance status, not advanced age, was associated ...
Liquid biopsy technologies, particularly circulating tumor DNA, or ctDNA, are changing how clinicians monitor hematologic ...
Red blood cell exchange transfusion (ET) reduced the risk of in-hospital death and 30-day readmission in patients with severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results